Yinghong Gao

Yinghong Gao (Yinghong Gao | LinkedIn; Yinghong Google Scholar) is a Venture Partner & VP of BD of Viva Biotech. She is responsible for the post investment management of many Viva portfolio companies as board members or board observers. One of the companies she sourced and managed DTx Pharma had recently been acquired by Novartis with a $500M upfront payment and a total deal size of $1B. She is also involved in business development in the innovative drug discovery contract service space. Yinghong has around 15 years of drug discovery experience working with Cytel Corporation, Neurocrine Biosciences and Arena Pharmaceuticals as a medicinal chemist and computational chemist, contributed to the discovery of Neurocrine's GnRH antagonist ORILISSA® and Arena’s S1P receptor modulator Etrasimod which had led to a $6.7B acquisition by Pfizer in 2022.